Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven G Terra

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Pharmaceutical Research|January 14, 2003
Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogeneticsJulie A Johnson, Steven G Terra
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 16, 2002
Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease managementLarisa M Humma, Steven G Terra
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 20, 2004
Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forwardSteven G Terra, Julie A Johnson
CPT: Pharmacometrics & Systems Pharmacology|May 12, 2023
A population pharmacokinetic and pharmacokinetic-pharmacodynamic analysis of vupanorsen from phase I and phase II studiesJae Eun Ahn, Steven G Terra, Jing Liu
Cardiovascular Diabetology|May 9, 2019
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trialsJie Liu, Annpey Pong, Silvina Gallo, et al.
Acute Cardiac Care|October 10, 2007
Non-traditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ?Yuval Konstantino, Robert Wolk, Steven G Terra, et al.
Diabetes, Obesity & Metabolism|February 9, 2018
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension studyRonnie Aronson, Juan Frias, Allison Goldman, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 11, 2020
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 TrialsSilvina Gallo, Roberto A Calle, Steven G Terra, et al.
Obesity (Silver Spring, Md.)|March 24, 2020
Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes MellitusSteven B Heymsfield, Annaswamy Raji, Silvina Gallo, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|March 31, 2009
Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery diseaseYuval Konstantino, Tu T Nguyen, Robert Wolk, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Pharmaceutical Research|January 14, 2003
Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogeneticsJulie A Johnson, Steven G Terra
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 16, 2002
Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease managementLarisa M Humma, Steven G Terra
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 20, 2004
Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forwardSteven G Terra, Julie A Johnson
CPT: Pharmacometrics & Systems Pharmacology|May 12, 2023
A population pharmacokinetic and pharmacokinetic-pharmacodynamic analysis of vupanorsen from phase I and phase II studiesJae Eun Ahn, Steven G Terra, Jing Liu
Cardiovascular Diabetology|May 9, 2019
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trialsJie Liu, Annpey Pong, Silvina Gallo, et al.
Acute Cardiac Care|October 10, 2007
Non-traditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ?Yuval Konstantino, Robert Wolk, Steven G Terra, et al.
Diabetes, Obesity & Metabolism|February 9, 2018
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension studyRonnie Aronson, Juan Frias, Allison Goldman, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 11, 2020
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 TrialsSilvina Gallo, Roberto A Calle, Steven G Terra, et al.
Obesity (Silver Spring, Md.)|March 24, 2020
Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes MellitusSteven B Heymsfield, Annaswamy Raji, Silvina Gallo, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|March 31, 2009
Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery diseaseYuval Konstantino, Tu T Nguyen, Robert Wolk, et al.
Pageof 6